A new trading day began on Friday, with Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) stock price down -3.31% from the previous day of trading, before settling in for the closing price of $16.29. CNTA’s price has ranged from $7.75 to $19.09 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 2.83%. With a float of $79.75 million, this company’s outstanding shares have now reached $131.66 million.
Let’s look at the performance matrix of the company that is accounted for 76 employees. In terms of profitability, gross margin is 89.52%, operating margin of -2342.65%, and the pretax margin is -2294.59%.
Centessa Pharmaceuticals plc ADR (CNTA) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Centessa Pharmaceuticals plc ADR is 39.43%, while institutional ownership is 55.19%. The most recent insider transaction that took place on Mar 20 ’25, was worth 918,060. In this transaction Chief Executive Officer of this company sold 55,000 shares at a rate of $16.69, taking the stock ownership to the 276,017 shares. Before that another transaction happened on Mar 20 ’25, when Company’s Officer proposed sale 55,000 for $16.35, making the entire transaction worth $899,250.
Centessa Pharmaceuticals plc ADR (CNTA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.37 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.83% per share during the next fiscal year.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Trading Performance Indicators
Here are Centessa Pharmaceuticals plc ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 21.52. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 300.09.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.54 in one year’s time.
Technical Analysis of Centessa Pharmaceuticals plc ADR (CNTA)
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) saw its 5-day average volume 0.95 million, a positive change from its year-to-date volume of 0.88 million. As of the previous 9 days, the stock’s Stochastic %D was 35.69%. Additionally, its Average True Range was 1.12.
During the past 100 days, Centessa Pharmaceuticals plc ADR’s (CNTA) raw stochastic average was set at 28.17%, which indicates a significant increase from 27.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.60% in the past 14 days, which was lower than the 57.39% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.46, while its 200-day Moving Average is $14.50. Nevertheless, the first resistance level for the watch stands at $16.34 in the near term. At $16.94, the stock is likely to face the second major resistance level. The third major resistance level sits at $17.24. If the price goes on to break the first support level at $15.45, it is likely to go to the next support level at $15.14. The third support level lies at $14.55 if the price breaches the second support level.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Key Stats
With a market capitalization of 2.07 billion, the company has a total of 131,845K Shares Outstanding. Currently, annual sales are 6,850 K while annual income is -151,090 K. The company’s previous quarter sales were 0 K while its latest quarter income was -42,570 K.
